The purpose of this study is to evaluate the efficacy and safety of SYH2068 injection in patients with elevated lipoprotein(a).

This is a multicenter, randomized, double-blind, parallel, placebo-controlled Phase II clinical trial aimed at evaluating the efficacy, safety, immunogenicity, and pharmacokinetic characteristics of SYH2068 injection in adult participants with elevated lipoprotein(a). The study consists of a screening period and a treatment period.

Inclusion Criteria:

1. Male or female participants ≥18 years of age;
2. Elevated Lp(a);
3. Participants who have used lipid-lowering drugs continue to use a stable dose, and those who have not used do not start new lipid-lowering drugs;
4. Presence of ASCVD or ASCVD risk stratification assessed as moderate or high risk;
5. Participants are able to understand and cooperate to complete this study, voluntarily participate in this study, and sign the ICF.

Exclusion Criteria:

1. Diseases that significantly affect Lp(a) during screening period,
2. Major or unstable cardiovascular events occurring from 3 months before signing the ICF to randomization;
3. Undergoing or expected to undergo peripheral arterial, coronary, or cerebrovascular revascularization surgery or other major surgery within 3 months prior to signing the ICF until randomization or during the study period;
4. NYHA class III-IV at the time of signing the ICF or LVEF <40% during the screening period;
5. Type 1 diabetes or hereditary hemorrhagic disorder at screening;
6. History of malignant tumor or suspected malignancy within 5 years prior to screening;
7. Use of drugs affecting Lp(a) within the specified period before screening or expected to use during the study period;
8. Allergy to oligonucleotide drugs;
9. Received any other clinical study treatment within 3 months prior to screening or within 5 half-lives of the investigational drug;
10. Female participants who are pregnant or breastfeeding at screening, or female / male participants who plan to conceive during the study and within 1 year after the last dose.